Clinical Utility in Cancer Patient Management
|
|
|
- Lynette Cannon
- 5 years ago
- Views:
Transcription
1 Clinical Utility in Cancer Patient Management National Cancer Policy Forum Workshop Oct 29-30, 2018 Lincoln Nadauld, MD PhD Executive Director, Precision Genomics Intermountain Healthcare
2 Disclosure Information I have the following financial relationships to disclose: Advisor: Navican, Ciitizen, Roche Consulting: Genentech Stockholder: TOMA Biosciences Employee of: Intermountain Healthcare - and - I will not discuss off label use of specific drugs and/or investigational use in my presentation.
3 Intermountain Healthcare: An Integrated System 22 Hospitals 2,800 Licensed Beds 180 Medical Group Clinics 875,000 SelectHealth Members
4 Precision Oncology Workflow Clinic Pathology Review Molecular Analysis (NGS) Molecular Tumor Board Day 1 Day 5 Day 7 Day 9 Day 2-4 Day 6 Day 8 Day 10 Biopsy or FFPE Sample Prep Bioinformatics Results and Treatment 4
5 MTB Interpretation included on the report Interp. in the report
6 Intermountain Precision Medicine Cohort Study Patients received standard trx within Intermountain 36 standard trx match: dx, age, gen, #prev. trx 61 with actionable mutation, and received targeted trx 36 genomics+trg trx match: dx, age, gen, #prev. trx 25 without match: dx, age, gen, prev. trx Assess: -PFS -Cost of care Assess: -PFS -Cost of care Haslem and Nadauld. JOP. 2016
7 Precision Oncology: Overall Survival Weeks after treatment start Standard chemotherapy (n=22) Avg. = 11.0 wks PFS Avg. = 25.8 wks overall survival Targeted cancer therapy (n=22) Healthcare costs ~$30 / week ~$70K / week Avg. = 21.4 wks PFS Avg. = 51.7 wks overall survival Haslem et al., Oncotarget. 2018
8 Precision Oncology Costs Control (N=22) Targeted (N=22) Difference Inpatient $552 $448 ($104) Outpatient $2,376 $1,167 ($1,209) ER $34 $45 $11 Rx drugs $346 $940 $594 Hospice $146 $9 ($137) Sequencing $0 $112 $112 Total/week $3,453 $2,720 ($734) Haslem et al., Oncotarget. 2018
9 Precision Oncology Costs $50,000 Costs per patient among Select Health members in the last 3 months of life, by site of care $45,000 $40,000 $35,000 $30,000 $25,000 $20,000 $15,000 $10,000 $5,000 $0 Total Inpatient Outpatient Office Rx Pharmacy ER/UC All other SelectHealth - Standard Tx (n=1,721) SelectHealth - Targeted Tx (n=93) Total Inpatient Outpatient Office Rx Pharmacy ER/UC All other SelectHealth - Standard Tx $46,940 $29,523 $7,425 $3,663 $1,415 $1,385 $1,177 SelectHealth - Targeted Tx $43,711 $15,535 $11,216 $6,265 $5,500 $1,469 $1, % -47.4% 51.1% 71.1% 288.7% 6.1% 5.5%
10 Genomic Testing now covered by local health plan
11 Precision Medicine Menu ICG100 TM Cancer Panel RxMatch TM Pharmacogenomics in Mental Health HerediGene TM Hereditary Cancer Panel All orderable and reportable within the EMR (Cerner)
12 Intermountain Biorepository 4.5 million archival samples Accumulated from 1975-present Longitudinal healthcare outcome data (30yrs)
13 Intermountain biorepository: Oncology Total distinct patients: ~150K 000s of patients with primary diagnosis Breast 15 Prostate 14 Gastrointestinal 11 Reproductive 10 Blood 10 Other 6 Lung 6 Skin 5 Thyroid 4 Bladder 3 Kidney 3 Brain/Spine 2 Pancreatic 1 Liver 13
14 Intermountain biorepository: CNS, Immunology & CVD CNS Total distinct patients: ~500K Immunology CVD Total distinct patients: ~200K Total distinct patients: ~400K 000s of patients with primary diagnosis Back and Spine Fatigue Carpal Tunnel & Other 67 Sleep Disorders 35 Headache E.g. includes ~2k AD patients 26 Seizures / Convulsions 9 Degenerative Disorders 9 Neuropathy 8 Dementia E.g. includes ~12k RA patients 104 Arthropathies 51 Autoimmune disorders 38 Enlarged lymph nodes, allergies & other E.g. includes ~12k IBD patients 33 Transplantation 15 Neoplasms 8 Immunodeficiency Disorders 6 Multiple Sclerosis 4 Lupus 151 Hypertension 149 Metabolic 136 Thrombus, Cardiomegaly & Other 94 Ischemic Heart Disease E.g. includes ~55k CAD patients 81 Cardiac Arrhythmias 55 Cerebrovascular 37 Edema 31 Arterial Disease 14
15 NGSOne: Whole Genome Product + Impact o Whole Genome, Whole Exome Sequencing, Whole Transcriptome o New external collaborations o NICU sequencing o Precision Nephrology o Biorepository (4.3M archival samples)
16 Acknowledgements Intermountain Precision Genomics: Derrick Haslem Gary Stone Pravin Mishra David Loughmiller Genomics Core Lab Cancer Clinical Program Sharanya Raghunath Jason Gillman Robin Romero Brent James Stanford University Jim Ford Hanlee Ji NCI AACR ASCO
The Intermountain Oncology Clinical Program: Present and Future
The Intermountain Oncology Clinical Program: Present and Future William T. Sause, MD Director of Radiation Oncology; Intermountain Healthcare; Murray, Utah Objectives: Define current status of the Cancer
Internal Medicine Certification Examination Blueprint
Internal Medicine Certification Examination Blueprint What Does the Examination Cover? The exam is designed to evaluate the extent of the candidate s knowledge and clinical judgment in the areas in which
Cancer Care Quality Program. Jennifer Malin, MD, PhD, Staff VP Clinical Strategy, Anthem Inc. VAHO Meeting April 2015
Cancer Care Quality Program Jennifer Malin, MD, PhD, Staff VP Clinical Strategy, Anthem Inc. VAHO Meeting April 2015 Off-Label Use Disclosure I do not intend to discuss an off-label use of a product during
University of Pittsburgh Cancer Institute UPMC CancerCenter. Uma Chandran, MSIS, PhD /21/13
University of Pittsburgh Cancer Institute UPMC CancerCenter Uma Chandran, MSIS, PhD chandran@pitt.edu 412-648-9326 2/21/13 University of Pittsburgh Cancer Institute Founded in 1985 Director Nancy Davidson,
Production Scientific EXECUTIVE SUMMARY. Quartile. Impact. factor. documents. Total of. Journal ISSN
.8. Scientific Production Journal ISSN Total of documents Impact factor Quartile Accident Analysis and Prevention 0001-4575 1.685 D1 1 1 1 1.116 Acta Paediatrica Acta Tropica 1 1 3 1 Age and Ageing 1 3
Premium Specialty: Pediatrics
Premium Specialty: Pediatrics Credentialed Specialties include: Adolescent Medicine, Pediatric Adolescent, and Pediatrics This document is designed to be used in conjunction with the UnitedHealth Premium
History of Oncology Research at Intermountain Healthcare
History of Oncology Research at Intermountain Healthcare Elizabeth Hale Hammond, MD, FACP Consulltant Pathologist, Intermountain Healthcare, Professor of Pathology, University of Utah School of Medicine;
Enterprise Interest Thermo Fisher Scientific / Employee
Enterprise Interest Thermo Fisher Scientific / Employee A next-generation sequencing assay to estimate tumor mutation load from FFPE research samples Fiona Hyland. Director of R&D, Bioinformatics Clinical
Realigning Reimbursement Policies for Quality and Value in Cancer Care
Realigning Reimbursement Policies for Quality and Value in Cancer Care Jennifer Malin, MD, PhD Medical Director, Oncology Solutions and Innovation Pay for Performance Summit Mini-Summit V: Innovative Payment
Creighton University Internal Medicine Residency Curriculum Cycle of 33 months
Creighton University Internal Medicine Residency Curriculum Cycle of 33 months Cardiology: 13 lectures and once a month EKG lecture, 25 total 1. EKG interpretation Once a month 2. Heart failure: 2 lectures.
New Patient Medical Questionnaire DATE:
New Patient Medical Questionnaire DATE: Patient Name: DOB: AGE: Other Physicians: Who can we thank for referring you to our practice? Pharmacy Name & Location:` Phone # CHIEF COMPLAINT What problems are
Patient Name (First, Middle, Last) Height Weight. Ethnicity Race Language. Address. City State Zip. Home Phone Cell Phone. Work Phone Other Phone
Patient Name (First, Middle, Last) Height Weight Date of Birth Social Security # Gender Male Female Ethnicity Race Language Address City State Zip Home Phone Cell Phone Work Phone Other Phone Email Occupation
RECOMMENDED COURSE ORDER
Although you have the flexibility to view the videos in any order, we strongly recommend that you watch the videos in the order in which your dashboard presents them regardless of how many videos you view
LECOM Health Ophthalmology
Patient Name: Date of Birth: New Patient Questionnaire Your answers will be used by your healthcare provider get an accurate history of your medical conditions and ocular concerns. If you are uncomfortable
Leveraging Analytics and Artificial Intelligence to Predict Health Risk
Leveraging Analytics and Artificial Intelligence to Predict Health Risk A case study on using machine learning to boost atrial fibrillation identification and anticoagulant drug use Arthur L. Forni, MD,
Correlations of Obesity, Comorbidity and Treatment: Implications for Survival Analysis and Interpretation
Correlations of Obesity, Comorbidity and Treatment: Implications for Survival Analysis and Interpretation Rachel Ballard-Barbash, MD, MPH Applied Research Program (ARP) Division of Cancer Control and Population
Disruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017
Disruptive innovation in molecular diagnostics Hilde Windels CEO Biocartis 25 March 2017 1 One of the key innovations in healthcare in the last decade PERSONALISED MEDICINE or HIGH PRECISION MEDICINE From
PHARMO Database Network
Pros & cons in Oncology studies PHARMO Myrthe Database van Herk-Sukel, Network PhD 1 Disclosure Myrthe van Herk-Sukel is an employee of the PHARMO Institute for Drug Outcomes Research. This independent
In your own words, please write the reason you are here. Please be specific, putting in dates as necessary. Use the back of the form if needed.
Name: SS# In your own words, please write the reason you are here. Please be specific, putting in dates as necessary. Use the back of the form if needed. Patient Medical, Surgical and Family History Review
別紙 No. 掲載雑誌名 ISSN Impact Factor (2016) 1 Acs Nano Acta Biomaterialia Acta Crystallographica Section D-Structural
別紙 1 Acs Nano 1936-0851 13.942 2 Acta Biomaterialia 1742-7061 6.319 3 Acta Crystallographica Section D-Structural Biology 0907-4449 2.114 4 Acta Neuropathologica 0001-6322 12.213 5 Acta Ophthalmologica
Cancer Genomics Testing: diagnostic yield and reimbursement
Cancer Genomics Testing: diagnostic yield and reimbursement Anthony N. Sireci, MD, MS Assistant Professor of Pathology and Cell Biology Columbia University Medical Center Assistant Director and Physician
Hereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG
Hereditary Breast and Ovarian Cancer 2015 Rebecca Sutphen, MD, FACMG Among a consecutive series of 11,159 women requesting BRCA testing over one year, 3874 responded to a mailed survey. Most respondents
Episodes of Care Risk Adjustment
Episodes of Care Risk Adjustment Episode Types Wave 1 Asthma Acute Exacerbation Perinatal Total Joint Replacement Wave 2 Acute Percutaneous Coronary Intervention COPD Acute Exacerbation Non-acute Percutaneous
Member-centered cancer care In Georgia
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions Member-centered cancer care In Georgia Ira Klein, MD, MBA, FACP GASCO Annual Meeting September 5, 2015 > One
Oncology 101. Cancer Basics
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
Integrating Behavioral Health into Primary Care: Collaborative-Care Models
Integrating Behavioral Health into Primary Care: Collaborative-Care Models Presented at the National Health Policy Forum September 17 th, 2013 Marc Avery, MD Clinical Associate Professor Associate Director
Updates in Cancer Genetics & Genomics
Updates in Cancer Genetics & Genomics Jennifer R. Klemp, PhD, MPH, MA Associate Professor of Medicine, Division of Clinical Oncology Director, Cancer Survivorship Co-Program Leader, Cancer Prevention and
Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011
Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Robert W. Carlson, M.D. Professor of Medicine Stanford University Chair, NCCN Breast Cancer Treatment Guidelines Panel Selection of
The Linked SEER-Medicare Data and Cancer Effectiveness Research
The Linked SEER-Medicare Data and Cancer Effectiveness Research Arnold L. Potosky, PhD Professor of Oncology Director of Health Services Research Georgetown University Medical Center Lombardi Comprehensive
What It Takes to Get Incorporation Into Guidelines and Reimbursement for Advanced Cancer Diagnostics: Lessons from Oncotype DX
What It Takes to Get Incorporation Into Guidelines and Reimbursement for Advanced Cancer Diagnostics: Lessons from Oncotype DX WSMOS Meeting Oct 2013 Steven Shak, MD Genomic Health Disclosure: October
City State Zip. Cell Phone. Other Phone. Gender Male Female Status Single Married Divorced Widowed. Height Weight EXERCISE Yes No Times per Week
Patient Name (First Middle Last) Date of Birth Social Security # Address City State Zip Home Phone Work Phone Cell Phone Other Phone Email Place of Birth Occupation Retired Yes No Gender Male Female Status
Surveillance and SEER Where are we going? NAACCR Meeting June 23, 2017 Lynne Penberthy MD, MPH
Surveillance and SEER Where are we going? NAACCR Meeting June 23, 2017 Lynne Penberthy MD, MPH Presentation Objectives Describe Future Role of Registries & Registrars Challenges to cancer surveillance
The American Healthcare System. Susan Haas, M.D, MSc. Healthcare Systems Engineering Institute Northeastern University May 27, 2015
The American Healthcare System Susan Haas, M.D, MSc. Northeastern University May 27, 2015 2 3 Provider Types Physician Nurse Pharmacist Dentist APC: NP, PA, CNM, NA 4 5 Internal Medicine Adolescent Medicine
Patient Information. Patient Name: DOB: Last First M.I. Home Address: City: State: Zip: Home Phn: Cell Phn: Alt. Phn: SSN:
Dr. Alvin Huang, M.D., F.A.C.E. 1650 W. Rosedale St. Suite 301, Fort Worth TX 76104 (P) 817-259-4333 (F) 817-820-0303 Patient Information Patient Name: DOB: Last First M.I. Home Address: City:_ State:
Daniel Lieber, Ph.D. Senior Scientist, Computational Biology Foundation Medicine, Cambridge, MA. AACR 2017: Clinical Biomarkers April 3, 2017
Validation & clinical feasibility of a comprehensive genomic profiling assay to identify likely immunotherapy responders through tumor mutational burden (TMB) Daniel Lieber, Ph.D. Senior Scientist, Computational
ICD-9-CM CODING FUNDAMENTALS CODING EXERCISES
Steps to Accurate Coding Underline the main term, then locate code: Stenosis of Carotid Artery Transient Ischemic Attack Gastrointestinal hemorrhage Degenerative Joint Disease Coronary Artery Disease Alcoholic
Multigene Panel Testing for Hereditary Cancer Risk
Multigene Panel Testing for Hereditary Cancer Risk Dana Zakalik, M.D. Director, Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Annual Meeting November 4, 2015 Outline
PATIENT HEALTH QUESTIONNAIRE Radiation Oncology
REVIEWED DATE / INITIALS Safety: Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: If YES, please list medication allergies: Do you have
Health Questionnaire
Patient Name Date of Birth Thank you for choosing Southern Cancer Center for your care. To help us best prepare for your appointment, please complete this form and bring it to your appointment. If you
c o m m u n i t y o u t r e a c h
c o m m u n i t y o u t r e a c h p r o g r a m knowledge of health care issues health education series Marion General Hospital s health education series consists of a kit with lesson plans and curriculum,
PATIENT HEALTH QUESTIONNAIRE Radiation Oncology
REVIEWED DATE / INITIALS Safety: Yes No Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: Yes No If YES, please list medication allergies:
For Office Use Only: MA complete Date of Visit / / mm/dd/yyyy. This form must be scanned into the medical record. Do not remove from clinic.
For Office Use Only: MA complete Date of Visit / / mm/dd/yyyy This form must be scanned into the medical record. Do not remove from clinic. UWMC Women s Health Care Center & SCCA Women s Cancer Center
Making the Most of Your Cancer Registry
www.champsods.com Making the Most of Your Cancer Registry Presenter: Toni Hare, Vice President CHAMPS Oncology Data Services Picture of girl here December 11, 2009 Learning Objectives Upon completion of
Field Underwriting Quickview
Field Underwriting Quickview For a selected list of medical conditions, the Field Underwriting Quickview outlines possible classifications and the circumstances when coverage may not be. For coverage provided
MEDICAL DATA SHEET For Patients 18 years of age and older
MEDICAL DATA SHEET For Patients 18 years of age and older NAME: DATE: / / AGE: DOB: / / 1. What is the main reason you are seeking a physician s advice? 2. Please list all allergies: Drug Allergies: Other
Syncope and Seizure Questionnaire
Syncope and Seizure Questionnaire World College of Neurology 2/79 Wheatley Drive Bull Creek WA 6149 T 08 93320488 F 08 93329988 Copyright 2011. All rights reserved. Patient Name: MAIN PROBLEM I am here
Adult Health History for New Patient
Adult Health History for New Patient Name: Birth Date: Today s Date: Preferred Pharmacy (name and location): Your answers on this form will help your health care provider get an accurate history of your
How much do you know about illnesses or health problems for your parents, grandparents, brothers, sisters, and/or children? 1 A lot Some None at all
Family Health History Please answer each question as honestly as possible. There are no right or wrong answers to nay of the questions. It is important that you answer as many questions as you can. We
Job Task Analysis for ARDMS Abdomen Data Collected: June 30, 2011
Job Task Analysis for ARDMS Abdomen Data Collected: June 30, 2011 Reported: Analysis Summary for: Abdomen Examination Survey Dates 06/13/2011-06/26/2011 Invited Respondents 6,000 Surveys with Demographics
Information contained in this listing is collected and maintained by the American Board of Internal Medicine.
1936-1940 1936 1937 1938 1939 1940 Decade Internal Medicine 27 209 90 227 255 808 1941-1950 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 Decade Internal Medicine 242 204 342 271 314 473 654 486 335
Certified Breast Care Nurse (CBCN ) Test Content Outline (Effective 2018)
Certified Breast Care Nurse (CBCN ) Test Content Outline (Effective 2018) I. Coordination of Care - 26% A. Breast health, screening, early detection, risk assessment and reduction 1. Issues related to
CA End of Life Option Act
CA End of Life Option Act The Experience at UC Davis Annual Advances in Oncology September 22, 2017 Nathan Fairman, MD MPH Medical Director UCDMC EOLOA Program Disclosures I have no relevant financial
Targeted Agent and Profiling Utilization Registry
Targeted Agent and Profiling Utilization Registry Richard L. Schilsky, MD, FACP, FASCO Senior Vice President and Chief Medical Officer American Society of Clinical Oncology Disclosure Information Richard
CUMULATIVE ILLNESS RATING SCALE (CIRS)
CUMULATIVE ILLNESS RATING SCALE (CIRS) The CIRS used in this protocol is designed to provide an assessment of recurrent or ongoing chronic comorbid conditions, classified by 14 organ systems. Using the
View from the Technology Evaluation Center (TEC)
View from the Technology Evaluation Center (TEC) Naomi Aronson, Ph.D. Executive Director, TEC Blue Cross and Blue Shield Association IOM Genomics Workshop December 4, 2007 Overview TEC perspective and
Evolve180 / Ideal Northwest Health Profile
Evolve180 / Ideal Northwest Health Profile ABOUT YOU First Name: Last Name: Address: City: State: Zip: Phone: Email: Date of Birth: Age: Height: Occupation: How did you find out about our program? Marital
All Other Medications, Dose Times per day Reason for taking the medication. Phone #
Patient Name: Date of Birth: _ Medical Record Number: Mailing Address: PO Box 29086 Thornton, CO 80229 Phone: 720.215.0700 Fax: 877.332.3131 Allergies Do you have Allergies Yes No If yes, please complete
o Kidney Cancer o Liver Cancer o Tremor o Tuberculosis o B12 Deficiency o Esophageal Cancer o Liver Disease o Pituitary Tumor o Uterine o Neurological
Adult New Patient Registration PATIENT DOB: / / MONTH DAY YEAR PATIENT NAME: LAST FIRST MI o Abnormal Heartbeat Patient Medical History: Please mark all that apply o Chronic Headaches o Hepatitis C o Neuropathy
NCI Community Cancer Centers Program
NCI Community Cancer Centers Program BIOSPECIMENS SURVIVORSHIP Andrew L. Salner, MD FACR Director, Helen & Harry Gray Cancer Center Hartford Hospital Hartford, CT Hartford Hospital 865 bed community and
Hu J, Gonsahn MD, Nerenz DR. Socioeconomic status and readmissions: evidence from an urban teaching hospital. Health Aff (Millwood). 2014;33(5).
Appendix Definitions of Index Admission and Readmission Definitions of index admission and readmission follow CMS hospital-wide all-cause unplanned readmission (HWR) measure as far as data are available.
Supplementary Tables. Supplementary Figures
Supplementary Files for Zehir, Benayed et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients Supplementary Tables Supplementary Table 1: Sample
USMLE STEP 2 CK REVIEW STUDY GUIDE
USMLE STEP 2 CK REVIEW STUDY GUIDE 2014 edition Brian Jenkins, MD Although you have the flexibility to view the videos in any order, we strongly recommend that you watch the videos in the order in which
Connections Between Autoimmune Disease & Cancer
February 6, 2018 Connections Between Autoimmune Disease & Cancer Dr. Reetesh Bose, PGY2 Supervisor: Dr. Jennifer Beecker, MD, CCFP(EM), FRCPC, DABD, FAAD University of Ottawa, Division of Dermatology Definitions
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
SCOPE OF PRACTICE. HEMATOLOGY and ONCOLOGY. -ordering / interpreting / performing appropriate diagnostic tests
SCOPE OF PRACTICE HEMATOLOGY and ONCOLOGY Care of the patients shall include, but not be limited to: -Performance of an appropriate history and physical exam -ordering / interpreting / performing appropriate
Non-Profit Startup Paradigm Launches Cancer Panel Based on DNA, RNA Sequencing
Non-Profit Startup Paradigm Launches Cancer Panel Based on DNA, RNA Sequencing April 11, 2014 By Tony Fong Non-profit diagnostics outfit Paradigm last month joined a growing list of entrants in the clinical
DATE OF BIRTH: MELANOMA INTAKE
MELANOMA INTAKE GENERAL INFORMATION How was your first diagnosed? (Check the diagnosis that describes your condition.) Melanoma Merkel Cell Carcinoma Squamous Cell Carcinoma Basal Cell Carcinoma Other
Integrating the Latest in Genomic Science into Modern Medical Practice
Integrating the Latest in Genomic Science into Modern Medical Practice Mayo Clinic Center for Individualized Medicine Datapalooza DC, 2017 4/21/2017 1 My Genome is an iron overloaded, lipid accumulating,
MU - Selection & Configuration of Measures
MU - Selection & Configuration of Measures Presenter: Christy Erickson October 14, 2011 Objectives Review the 15 Core Measures and highlight some findings from the field Discuss the MU Menu and Clinical
Can point of care cardiac biomarker testing guide cardiac safety during oncology trials?
Can point of care cardiac biomarker testing guide cardiac safety during oncology trials? Daniel J Lenihan, MD Professor, Division of Cardiovascular Medicine Director, Clinical Research Vanderbilt University
Effective Date: TBD Version: 1.0 (Revised: 6/11/2014)
Protocol Title: Hypertension Effective Date: TBD Version: 1.0 (Revised: 6/11/2014) Approval By: TBD Planned Review Date: TBD 1 Purpose & Objective This protocol provides evidence-based care recommendations
Health Profile. Last Name: First Name: Address: Apt/Unit: # City: State: Zip/Postal Code: Phone: Cell:
1 Health Profile Date: / / / Dietary consultation involves a health profile. The purpose of the health profile is not to establish a diagnosis, but rather to determine a client s health status in order
Why Pathway Genomics. Advanced Genetic Testing Laboratory. General Health and Wellness. Liquid Biopsy. Hereditary Cancer.
Advanced Genetic Testing Laboratory General Health and Wellness Liquid Biopsy Hereditary Cancer Pharmacogenomics Carrier Screening Why Pathway Genomics Founded in 2008, Pathway Genomics offers digital
UAB P30 CORE A: The Hepato-Renal Fibrocystic Diseases Translational Resource
PKD Foundation UAB P30 CORE A: The Hepato-Renal Fibrocystic Diseases Translational Resource http://www.arpkdstudies.uab.edu/ Director: Co-Director: Lisa M. Guay-Woodford, MD William E. Grizzle, MD, PhD
Apt. /unit: City: State: Zip Code:
Health Profile Date: Dietary consultation involves a health profile. The purpose of the health profile is not to establish a diagnosis, but rather to determine a client s health status in order to guide
To Bundle or Not to Bundle?
To Bundle or Not to Bundle? Ronald Barkley, CCBD Group Mark Krasna, MD, Meridian Cancer Care Constantine Mantz, MD, 21 st Century Oncology Joseph O Hara, Horizon Blue Cross Lee Newcomer, MD, United Healthcare
Interventional Pain Medicine. P. Tennent Slack, M.D. Dr. Greg Jackson, M.D. Ben Fleming, PA-C
Interventional Pain Medicine P. Tennent Slack, M.D. Dr. Greg Jackson, M.D. Ben Fleming, PA-C Gainesville Braselton Medical Park 1, Suite 300 Medical Plaza B, Suite 402 1315 Jesse Jewell Parkway 1404 River
Providence Medical Group
Providence Medical Group To our valued patients: In order to provide you with our full attention when you come for an appointment, we would like to ask you to be aware of the following guidelines. Insurance
A Time- and Resource-Efficient Method for Annually Auditing All Reporting Hospitals in Your State: the Inpatient & Outpatient Hospital Discharge Files
A Time- and Resource-Efficient Method for Annually Auditing All Reporting Hospitals in Your State: the Inpatient & Outpatient Hospital Discharge Files By Dr. Martin A. Whiteside Director, Office of Cancer
Hamilton Niagara Haldimand Brant LHIN. Current State Health System Utilization and Performance by PAG
Hamilton Niagara Haldimand Brant LHIN Current State Health System Utilization and Performance by PAG A summary current state data profile has been collected for PAGs where data is available PAG level data
Using Observation and Inpatient Metrics to Maximize Net Reimbursement
Using Observation and Inpatient Metrics to Maximize Net Reimbursement Colleen Hall, Crowe Horwath Stephen Crouch MD, Advocate Good Samaritan Hospital 2 Objectives Identify industry benchmarks related to
Letter to the AMGA Board of Directors...1 Introduction...3
Table of Contents Letter to the AMGA Board of Directors...1 Introduction...3 Section I: Executive Summary Survey at a Glance...6 Participant Profile...10 Survey Methodology...18 How to Use This Report...21
MEDICAL DATA SHEET For Patients 18 years of age and older
MEDICAL DATA SHEET For Patients 18 years of age and older NAME: DATE: / / AGE: DOB: / / 1. What is the main reason you are seeking a physician s advice? 2. Please list all allergies: Drug Allergies: Other
Weight 1 year ago (lb):
Health Profile Dietary consultation involves a health profile. The purpose of the health profile is not to establish a diagnosis, but rather to determine a client s health status in order to guide his
SAMPLE SYSTEM INNOVATION/QUALITY IMPROVEMENT Activities Sections. Alicia Neu, M.D. December 1, 2011
SAMPLE SYSTEM INNOVATION/QUALITY IMPROVEMENT Activities Sections Alicia Neu, M.D. December 1, 2011 SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVTIES Publications 1. CMS- Supplemental Report: A study
Leveraging Your Cancer Registry: A Strategy for Survey Success
CoC-trained consultants on staff Leveraging Your Cancer Registry: A Strategy for Survey Success Toni Hare, RHIT, CTR CoC-trained Consultant Vice President, CHAMPS Oncology November 27, 2012 Georgia s Best
Is Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
MCKAY UROLOGY LINCOLNTON OFFICE PATIENT HISTORY FORM
Patient name: MRN #: Current Medications (prescription and over the counter medications including vitamins, herbs, aspirin, antacids, injectables, hormones and birth control medication) If you brought
Pediatric Oncology. Vlad Radulescu, MD
Pediatric Oncology Vlad Radulescu, MD Objectives Review the epidemiology of childhood cancer Discuss the presenting signs and symptoms, general treatment principles and overall prognosis of the most common
Disclosures. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.
ALL in AYAs: Health Outcomes as a Criterion for Selecting Optimal Therapy David R. Freyer, DO, MS Director, Survivorship and Supportive Care Program, Children s Center for Cancer and Blood Diseases, Children
Reliable Evaluation of Prognostic & Predictive Genomic Tests
Reliable Evaluation of Prognostic & Predictive Genomic Tests Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov Different Kinds of Biomarkers Prognostic
What is the Oncotype DX test?
Patient & Family Guide 2018 What is the Oncotype DX test? www.nscancercare.ca What is the Oncotype DX test? Information for women diagnosed with early-stage breast cancer What is the Oncotype DX test?
IMPACT OF HCV THERAPY ON METABOLISM AND PUBLIC HEALTH
IMPACT OF HCV THERAPY ON METABOLISM AND PUBLIC HEALTH Mitchell L Shiffman, MD Director Health System Richmond and Newport News, VA Medical Group Good Help to Those in Need DISCLOSURES CONFLICTS OF INTEREST
Fitting the Treatment to the Patient Roche Personalized Healthcare. February 24, 2012
Fitting the Treatment to the Patient Roche Personalized Healthcare February 24, 2012 Roche Group Pharmaceuticals Roche Pharma Genentech Chugai Applied Science Molecular Professional Tissue Diabetes Care
We are an academic institution What does that mean?
DERMATOLOGY & CUTANEOUS SURGERY We are an academic institution What does that mean? USF Health is an academic institution where future healthcare providers are trained. Below is a description of the different
Cancer Gene Panels. Dr. Andreas Scherer. Dr. Andreas Scherer President and CEO Golden Helix, Inc. Twitter: andreasscherer
Cancer Gene Panels Dr. Andreas Scherer Dr. Andreas Scherer President and CEO Golden Helix, Inc. scherer@goldenhelix.com Twitter: andreasscherer About Golden Helix - Founded in 1998 - Main outside investor:
Providing Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
Review of Systems NAME: DATE OF BIRTH: DATE COMPLETED: Dear Patient,
LOS ANGELES CANCER NETWORK NEW PATIENT HEALTH QUESTIONNAIRE NAME: DATE OF BIRTH: DATE COMPLETED: Dear Patient, In order to offer optimal care for you, we need to understand your complete health status
National Voluntary Consensus Standards for Patient Outcomes Table of Measures Submitted-Phase 2 As of March 5, 2010
National Voluntary Consensus Standards for Patient Outcomes Table of s Submitted-Phase 2 As of March 5, 2010 Note: This information is for personal and noncommercial use only. You may not modify, reformat,
NHOLUA. September 20, 2016 Lincoln, NE
NHOLUA September 20, 2016 Lincoln, NE UNDERWRITING BREAST CANCER, A NEW APPROACH Dr Robert Lund Basics in Determination of Breast Cancer Prognosis Age at Diagnosis Tumor Size Lymph Node Status Title of